A metabolomic study reveals novel plasma lyso-Gb3 analogs as fabry disease biomarkers

Current Medicinal Chemistry

Volumn 20, Issue 2, 2013, Pages 280-288

  Dupont, F O ^a   Gagnon, R ^a   Boutin, M ^a   Auray Blais, C ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Biomarkers; Fabry disease; Metabolomics; OPLS DA; Plasma; Qtof mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE DERIVATIVE; GLOBOTRIAOSYLCERAMIDE; HYDROGEN; SPHINGOSINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; PROTEIN ANALYSIS; PROTEIN MODIFICATION; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84877987576     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804806685     Document Type: Article

References (24)

1. Vega-Vega, O.; Pérez-Gutiérrez, A.; Correa-Rotter, R. Fabry-Anderson disease: current state of knowledge. Rev. Invest. Clin., 2011, 63(3), 314-321.
2. Meikle, P.J; Hopwood, J.J.; Clague, A.E.; Carey, W.F. Prevalence of lysosomal storage disorders. JAMA, 1999, 281, 249-254. (Pubitemid 29058114)
3. Spada, M.; Pagliardini, S.; Yasuda, M.; Tukel, T.; Thiagarajan, G.; Sakuraba, H.; Ponzone, A.; Desnick, R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet., 2006, 79, 31-40. (Pubitemid 43927374)
4. Clarke, J.T.R. Narrative review: Fabry disease. Ann. Intern. Med., 2007, 146, 425-433. (Pubitemid 351650579)
5. Mills, K.; Morris, P.; Lee, P.; Vellodi, A.; Waldek, S.; Young, E.; Winchester, B. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J. Inherit. Metab. Dis., 2005, 28, 35-48. (Pubitemid 40253982)
6. Auray-Blais, C.; Cyr, D.; Ntwar, A.; West, M.L.; Cox-Brinkman, J.; Bichet, D.G.; Germain, D.P.; Laframboise, R.; Melancon, S.B.; Stockley, T.; Clarke, J.T.R.; Drouin, R. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol. Genet. Metab., 2008, 93, 331-340. (Pubitemid 351192345)
7. Auray-Blais, C.; Millington, D.S.; Young, S.P.; Clarke, J.T.R.; Schiffmann, R. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease. J. Inherit. Metab. Dis., 2009, 32, 303-308.
8. Auray-Blais, C.; Cyr, D.; Mills, K.; Giguére, R.; Drouin, R. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J. Inherit. Metab. Dis., 2007, 30, 106.
9. Zhang, X.K.; Elbin, C.S.; Chuang, W.L.; Cooper, S.K.; Marashio, C.A.; Beauregard, C.; Keutzer, J.M. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin. Chem., 2008, 54, 1725-1728.
10. Whitfield, P.D.; Calvin, J.; Hogg, S.; O'Driscoll, E.; Halsall, D.; Burling, K.; Maguire, G.; Wright, N.; Cox, T.M.; Meikle, P.J.; Deegan, P.B. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J. Inherit. Metab. Dis., 2005, 28, 21-33. (Pubitemid 40253981)
11. Auray-Blais, C.; Ntwari, A.; Clarke, J.T.R.; Warnock, D.; Oliveira, J.P.F.S.; Young, S.P.; Millington, D.S.; Bichet, D.G.; Sirrs, S.; West, M.L.; Casey, R.; Wu, W.L.; Keutzer, J.; Zhang, K.; Gagnon, R. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin. Chim. Acta, 2010, 411, 1906-1914.
12. Aerts, J.M.; Groener, J.E.; Kuiper, S.; Donker-Koopman, W.E.; Strijland, A.; Ottenhof, R.; van Roomen, C.; Mirzaian, M.; Wijburg, F.A.; Linthorst, G.E.; Vedder, A.C.; Rombach, S.M.; Cox-Brinkman, J.; Somerharju, P.; Boot, R.G.; Hollak, C.E.; Brady, R.O.; Poorthuis, B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci., 2008, 105, 2812-2817. (Pubitemid 351723626)
13. Togawa, T.; Kodama, T.; Suzuki, T.; Sugawara, K.; Tsukimura, T.; Ohash, T.; Ishig, N.; Suzuki, K.; Kitagawa, T.; Sakuraba, H. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol. Genet. Metab., 2010, 100, 257-261.
14. Rombach, S.M.; Dekker, N.; Bouwman, M.G.; Linthorst, G.E.; Zwinderman, A.H.; Wijburg, F.A.; Kuiper, S.; vd Bergh Weerman, M.A.; Groener, J.E.M.; Poorthuis, B.J.; Hollak, C.E.M.; Aerts, J.M.F.G. Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease. Biochim. Biophys. Acta, 2010 1802(9), 741-748.
15. Sanchez-Nio, M.D.; Sanz, A.B.; Carras, S.; Saleem, M.A.; Mathieso, P.W.; Valdivielso, J.M.; Ruiz-Ortega, M.; Egido, J.; Ortiz, A. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol. Dial. Transplant., 2011, 26, 1797-1802.
16. van Breemen, M.J.; Rombac, S.M.; Dekker, N.; Poorthuis, B.J.; Linthorst, G.E.; Zwinderman, A.H.; Breunig, F.; Wanner, C.; Aerts, J.M.; Hollak, C.E. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim. Biophys. Acta, 2011,1812, 70-76.
17. Togawa, T.; Kawashima, I.; Kodama, T.; Tsukimura, T.; Suzuki, T.; Fukushige, T.; Kanekura, T.; Sakuraba, H. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem. Biophys. Res. Commun., 2010, 399(4), 716-720.
18. Fiehn, O.; Kristal, B.; van Ommen, B.; Sumne, L.W.; Sansone, S.A.; Taylor, C.; Hardy, N.; Kaddurah-Daouk, R. Establishing reporting standards for metabolomic and metabonomic studies: A call for participation. OMICS, 2006, 10(2), 158-163. (Pubitemid 44298603)
19. Mamas, M.; Dunn, W.B.; Neyses, L.; Goodacre, R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch. Toxicol., 2011, 85(1), 5-17.
20. Stewart, J.D.; Bolt, H.M. Metabolomics: biomarkers of disease and drug toxicity. Arch. Toxicol., 2011, 85(1), 3-4.
21. Auray-Blais, C.; Gagnon, R.; Clarke, J.T.R.; Young, S.P.; Millington, D.S. Metabolomics, biomarker discovery and Fabry disease: an efficient platform is necessary! Clin. Ther., 2009, 31, S24-S25.
22. Hsu, FF.; Tu, J. Structural determination of glycosphingolipids as lithiated adducts by electrospray ionization mass spectrometry using low-energy collisional-Activated dissociation on a triple stage quadrupole instrument. J. Am. Soc. Mass Spectrom., 2001, 12, 61-79.
23. Merrill, Jr. A.H.; Sandh, K. Sphingolipids: metabolism and cell signaling, In: D.E. Vance and J.E. Vance (Eds.) Biochemistry of Lipids, Lipoproteins and Membranes, 4th ed.; Elsevier Science B.V., Amsterdam, 2002; Chapter 14.
24. Karlsson, K.A. On the chemistry and occurence of sphingolipid long-chain bases. Chem. Phys. Lipids, 1970, 5, 6-43.